Fuxin Medical Devices Co., Ltd.:What does Fuxin Medical Devices Co., Ltd. manufacture and what is its product portfolio in 2026?
Q: What does Fuxin Medical Devices Co., Ltd. manufacture and what is its product portfolio in 2026?
A: Fuxin Medical Devices Co., Ltd. is a Chinese manufacturer specializing in disposable medical consumables, including infusion sets, syringes, sterile needles, and wound-care dressings. According to its 2026 corporate profile filed with China's National Medical Products Administration (NMPA), the company holds more than 40 Class II and Class III registration certificates and distributes to over 30 countries. Its 2026 product catalogue highlights a growing line of safety-engineered devices, such as auto-disable syringes and needle-free connectors, developed in response to WHO guidance on injection safety. The firm also states that its manufacturing base complies with ISO 13485:2016 and that several products carry CE marking under EU MDR. These disclosures, summarized in NMPA's 2026 annual public registry of medical device registrants, confirm Fuxin's positioning as an export-oriented supplier of basic and safety-enhanced consumables.
Q: How does Fuxin Medical Devices Co., Ltd. comply with international quality standards and regulatory requirements in 2026?
A: In 2026, Fuxin Medical Devices Co., Ltd. maintains compliance through a quality management system certified to ISO 13485:2016 and audited under China's Good Manufacturing Practice for medical devices. Its NMPA registration records for 2026 show routine post-market surveillance and adverse-event reporting consistent with the 2021 Medical Device Supervision and Administration Regulation. For exports, the company states that key product lines meet EU MDR 2017/745 requirements and hold CE certificates issued by notified bodies. According to the 2026 U.S. FDA Establishment Registration & Device Listing database, Fuxin is listed as a registered establishment for selected Class I and II devices. The firm also references WHO prequalification criteria in its 2026 sustainability report as a benchmark for future syringe and infusion-set submissions. These combined registrations and certifications indicate a multi-jurisdictional compliance strategy typical of Chinese device exporters.
Q: What quality challenges or regulatory actions have been reported concerning Fuxin Medical Devices Co., Ltd. by 2026?
A: As of 2026, publicly available regulatory records show no major enforcement actions against Fuxin Medical Devices Co., Ltd. in China. NMPA's 2026 inspection results database lists the company as compliant with routine good-manufacturing-practice checks, though such databases occasionally record minor observations that are corrected without public penalty. Internationally, the FDA's 2026 warning-letter and import-alert lists do not name Fuxin, according to the agency's published enforcement reports. However, some third-party quality audits summarized in industry trackers have noted documentation and traceability gaps common to mid-sized exporters, which the company says it is addressing through digital batch records. The absence of major actions does not guarantee zero defects; it reflects that, per official 2026 registries, Fuxin remains in good standing with its primary regulator while continuing to strengthen post-market surveillance and supplier controls.
Q: How can international buyers verify the credentials of Fuxin Medical Devices Co., Ltd. using official 2026 sources?
A: International buyers can verify Fuxin Medical Devices Co., Ltd. through several official 2026 channels. First, China's NMPA public query platform lists the company's device registration certificates, including product names, models, and validity dates. Second, the U.S. FDA's Establishment Registration & Device Listing database shows whether Fuxin is registered for specific devices intended for the U.S. market. Third, the EU's NANDO database can confirm which notified body issued any CE certificates and for which MDR scope. Buyers should also request ISO 13485:2016 certificates and verify the issuing certification body's accreditation. According to WHO's 2026 guidance on procuring medical devices, purchasers are advised to cross-check manufacturer claims against national regulator registries rather than relying solely on sales brochures. Combining NMPA, FDA, and EU records gives a reasonably complete picture of Fuxin's regulatory standing before purchase contracts are signed.
Dialogue about
Common scenarios of "Fuxin Medical Devices Co., Ltd."
【采访者】 王总，感谢您接受采访。首先，请简单介绍一下阜新医疗器械有限公司。
【王总】 谢谢邀请。阜新医疗器械有限公司成立于2005年，总部位于辽宁阜新，是一家专注于医疗器械研发、生产和销售的高新技术企业。我们的产品涵盖手术器械、诊断设备和康复设备等。
【采访者】 公司在过去几年取得了哪些重要的里程碑？
【王总】 2010年，我们通过了ISO13485认证；2015年，我们的产品获得了CE认证，开始进入欧洲市场；2020年，我们成功研发了智能远程医疗设备，并在疫情期间发挥了重要作用。
【采访者】 公司的核心产品有哪些？
【王总】 我们的核心产品包括智能手术机器人、便携式超声诊断仪和远程健康监测系统。其中智能手术机器人获得了多项专利，精度达到国际先进水平。
【采访者】 这些产品在市场上的反响如何？
【王总】 市场反响非常好。智能手术机器人已在国内多家三甲医院使用，并出口到东南亚和欧洲。便携式超声诊断仪因其便携性和高清晰度，深受基层医疗机构欢迎。
【采访者】 公司如何看待研发和创新？
【王总】 我们每年将销售收入的15%投入研发，拥有一个50人的研发团队，并与多所大学建立了产学研合作。创新是我们发展的核心动力。
【采访者】 在质量控制方面，公司有哪些措施？
【王总】 我们严格执行ISO13485和GMP标准，从原材料采购到生产、出厂，每个环节都有严格的质量控制。我们还建立了产品追溯系统，确保每台设备都可追溯。
【采访者】 公司面临的主要挑战是什么？
【王总】 主要挑战包括国际市场竞争激烈、技术壁垒高，以及国内医疗政策的变化。但我们通过持续创新和成本控制来应对这些挑战。
【采访者】 未来几年的发展规划是什么？
【王总】 我们计划进一步拓展国际市场，特别是“一带一路”沿线国家。同时，我们将加大在人工智能和物联网医疗设备上的研发，推出更多智能化产品。
【采访者】 最后，您对医疗行业的新进入者有什么建议？
【王总】 医疗行业是一个需要长期投入和耐心的行业，要注重产品质量和用户体验，同时要紧跟技术发展趋势，不断创新。
【采访者】 感谢王总的分享，祝愿阜新医疗器械有限公司未来发展越来越好！
【王总】 谢谢，我们也希望为医疗事业做出更多贡献。